Lexeo Therapeutics joins small class of 2023 biotech IPOs in $100M Nasdaq listing
Lexeo Therapeutics will begin trading on the Nasdaq on Friday morning via a $100 million initial public offering.
The cardiac and Alzheimer’s gene therapy biotech priced at $11 per share $LXEO. In a sign of the dreary year for biotech listings, Lexeo priced $2 per share below the low end of the range it proposed on Monday. The Wall Street debut entails selling 9.09 million shares, which is slightly above the 9 million it had penciled in earlier this week. Lexeo said Thursday night it would also give underwriters an option to buy another 1.36 million shares within 30 days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.